Synthesis, Characterization, and Anti-parasitic Activity Evaluation of the Synthesized Chalcone against Toxoplasma Gondii Isolated from Cases of Abortion in Al-Najaf City

Toxoplasmosis is a well-known and widespread parasite infection. Although diagnosis has come a long way, therapeutic approaches have not changed since the 1940s. Using SOCl2/EtOH as a catalyst, the Claisen-Schmidt condensation method has been used in this study to effectively synthesize chalcone. The anti-parasitic effect of the synthesized chalcone was evaluated at doses of 1, 10, 50, 100, 250, 500, and 1000 μg/ml against isolated Toxoplasma Gondii from aborted cases compared with spiramycin. The isolated T. Gondii in this therapeutic investigation was used as strong positive specimens for inoculum on Vero cells for parasite propagation. A significant reduced the fold expression values (2^-∆∆CT), which are a measure of how well chalcone inhibits the proliferation of parasites. Compared with spiramycin, which demonstrated an IC50 of 281.19 g/mL, chalcone has an inhibitory concentration (IC50) of 142.9 μg/mL. The results of this study reveal that chalcone can be used as a medication to treat toxoplasmosis because it had an antiparasitic impact on T. Gondii. To assess the therapeutic index of chalcone, molecular, synergistic, and in vivo monitoring investigations are essential.